Evidence map›Paper›PMID 41803403›Full record

Trial reportLeukemia2026

Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?

Dorothée Selimoglu-Buet, Sylvie Chevret, Valeria Santini, Sylvain Thépot, Margot Morabito, Lionel Adès, Lucie Laplane, Aristoteles Giagounidis, Nathalie Droin, Michael Lübbert and 18 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02214407 (A Randomized Phase III Study of Decitabine), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02214407 phase3completednot on this map

A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)

TypeinterventionalSponsorGroupe Francophone des MyelodysplasiesRan2014 to 2021Enrolled170ConditionsMDSArmsDecitabine, HYDROXYUREA
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Dorothée Selimoglu-BuetGroupe Francophone des Myélodysplasies, F-75010, Paris, France.ORCID 0000-0002-3565-2709
Sylvie ChevretService de Biostatistique et informatique médicale, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France.
Valeria SantiniMDS Unit, DMSC; AOU Careggi, University of Florence, Florence, Italy.ORCID 0000-0002-5439-2172
Sylvain ThépotGroupe Francophone des Myélodysplasies, F-75010, Paris, France.
Margot MorabitoUniversité Paris Saclay, INSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Lionel AdèsGroupe Francophone des Myélodysplasies, F-75010, Paris, France.ORCID 0000-0002-9020-8766
Lucie LaplaneUniversité Paris Saclay, INSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.ORCID 0000-0003-0185-3323
Aristoteles GiagounidisMarien Hospital, Klinik für Hämatologie, Onkologie und klinische Immunologie, D-40479, Düsseldorf, Germany.
Nathalie DroinUniversité Paris Saclay, INSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.ORCID 0000-0002-6099-5324
Michael LübbertDeutsche MDS-Studiengruppe, D-04103, Leipzig, Germany.ORCID 0000-0003-1186-1650
Rosa SapenaGroupe Francophone des Myélodysplasies, F-75010, Paris, France.
Stanislas NimubonaGroupe Francophone des Myélodysplasies, F-75010, Paris, France.
Jose Miguel Torregrosa-DiazGroupe Francophone des Myélodysplasies, F-75010, Paris, France.
Ulrich GermingDeutsche MDS-Studiengruppe, D-04103, Leipzig, Germany.
Anna Maria PelizzariFondazione Italiana Sindromi Mielodisplastiche (FISiM-ets), Bologna, Italy.
Sophie ParkGroupe Francophone des Myélodysplasies, F-75010, Paris, France.
Nadja JaekelDeutsche MDS-Studiengruppe, D-04103, Leipzig, Germany.ORCID 0000-0001-6162-515X
Georgia MetzgerothDeutsche MDS-Studiengruppe, D-04103, Leipzig, Germany.
Francesco OnidaFondazione Italiana Sindromi Mielodisplastiche (FISiM-ets), Bologna, Italy.ORCID 0000-0002-2991-3474
Franciane PaulGroupe Francophone des Myélodysplasies, F-75010, Paris, France.
Andrea PatriarcaFondazione Italiana Sindromi Mielodisplastiche (FISiM-ets), Bologna, Italy.
Aspasia StamatoullasGroupe Francophone des Myélodysplasies, F-75010, Paris, France.
Katharina GötzeDeutsche MDS-Studiengruppe, D-04103, Leipzig, Germany.ORCID 0000-0002-6276-8002
Fatiha ChermatService de Biostatistique et informatique médicale, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France.
Uwe PlatzbeckerDeutsche MDS-Studiengruppe, D-04103, Leipzig, Germany.ORCID 0000-0003-1863-3239
Pierre FenauxGroupe Francophone des Myélodysplasies, F-75010, Paris, France.
Eric SolaryGroupe Francophone des Myélodysplasies, F-75010, Paris, France.ORCID 0000-0002-8629-1341
Raphael ItzyksonGroupe Francophone des Myélodysplasies, F-75010, Paris, France. raphael.itzykson@aphp.fr.ORCID 0000-0003-2139-6262

Funding

Association Laurette Fugain (Laurette Fugain) ALF 2021/06Institut National Du Cancer (French National Cancer Institute) INCa_19428Institut National Du Cancer (French National Cancer Institute) INCa-DGOS-INSERM-ITMO Cancer_18008
6 · The paper itself

Abstract

Whether mitigation of myeloproliferation improves prognosis of CMML independently of bone marrow response is unknown. Flow-defined classical monocytes (cMo) and immature granulocytes (iGRAN) have not yet been studied as biomarkers of response. We inspected the prognostic value of WBC, circulating monocytes, cMo and iGRANs in the 120 DACOTA (NCT02214407) patients randomized to decitabine (n = 63) or hydroxyurea (n = 57) evaluated after 3 cycles with BM aspiration and complete blood count. Across arms, 59% and 56% patients had monocytes > 1 × 10

Indexed as

Leukemia, Myelomonocytic, ChronicAgedDecitabineFemaleGranulocytesHumansHydroxyureaMaleMonocytesPrognosisDecitabineHydroxyurea

Identifiers

PMID41803403
PMCPMC13056520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.